Verici Dx plc, a pioneer in advanced clinical diagnostics for organ transplant (AIM: VRCI), has achieved a significant milestone by obtaining clinical laboratory accreditation from the New York State Department of Health (NYSDOH) Clinical Laboratory Evaluation Program (CLEP). This accreditation validates the Company's commitment to high-quality testing standards. Additionally, Verici Dx plc has received approval from the NY state for Tutivia™, its innovative blood-based laboratory developed test (LDT). Tutivia™ offers a predictive risk score that is user-friendly and data-driven, providing valuable insights for healthcare professionals. This recognition reinforces Verici Dx plc's position as a leader in the field of organ transplant diagnostics.